DailyIQ
|
Sector:Consumer DefensiveAll sectors
Last updated 1 minute ago

CLX·The Clorox Company

$.
+. (+.%)
After Hours
High
$97.96
Open
$97.00
Market Cap
11.56B
52W High
$132.03
Low
$94.86
P. Close
$96.27
P/E
15.30
52W Low
$84.70
Fwd P/E
57.83
DailyIQ Est.
$95.89
Technical Score (1D)
45
NEUTRAL
News Sentiment
47
MIXED
BNP Paribas Exane has cut Clorox’s price target to $95 from $97, signaling a shift in its earnings outlook. The downgrade reflects concerns over earnings growth and margin pressure within the consumer staples sector. Despite the lower target, the bank maintains a neutral rating, indicating no change in its recommendation stance. This adjustment may dampen investor enthusiasm and could lead to tighter trading ranges in the next few days. The price target cut underscores the expectation that Clorox’s profitability may not keep pace with peers. Traders should watch for the upcoming earnings release, as guidance on cost‑control measures will test the new valuation. Any surprise in earnings or margin improvement could reverse the downward bias and lift short‑term sentiment. Conversely, a lack of progress on cost control could reinforce the neutral stance and keep the stock within a narrower band. Monitoring the company’s quarterly guidance will be key to assessing whether the price target adjustment holds or needs revisiting.
Earnings Summary
Clorox, a global consumer staples manufacturer, focuses on household and healthcare essentials through its Health and Wellness, Household, Lifestyle, and International segments, delivering trusted brands such as Clorox, Glad, and Brita across mass merchants, grocery stores, and online channels. In the defensive consumer sector, the company has maintained a steady presence by meeting everyday consumer demands since 1913. In the most recent two quarters with results—Q3 2025 and Q2 2026—Clorox reported EPS of $0.85 and $1.39, respectively, and revenue of $1.43 billion and $1.67 billion, both up from the prior two quarters of Q2 2025 and Q1 2025, which saw EPS of $1.25 and $1.09 and revenue of $1.53 billion and $1.67 billion; the company consistently beat analyst estimates in all six quarters reported, with EPS exceeding guidance in Q4 2024, Q1 2025, Q2 2025, Q3 2025, Q2 2026, and Q3 2026. Over the past year, revenue has remained largely flat, with Q3 2025 revenue slightly below Q4 2024 and Q2 2026 revenue marginally below Q2 2025, while EPS has trended downward from $1.55 in Q4 2024 to $0.85 in Q3 2025, indicating a deceleration in profitability despite consistent beats; the company has also maintained a stable dividend yield above 5 %. Recent analyst commentary highlights divergent views—UBS lifted its target to $100 citing confidence in earnings, while JPMorgan cut to $92 amid concerns over rising input costs and competition, and Goldman Sachs trimmed its target to $77, underscoring uncertainty around margin recovery; the upcoming Q4 2026 earnings webcast on August 3 will be pivotal for assessing guidance revisions, cost‑containment progress, and the impact of the new COO on operational efficiency. Investors should watch for any revisions to fiscal‑year guidance, margin trends, and commentary on commodity cost updates, as these factors will shape Clorox’s near‑term valuation and investor sentiment.

EPS

EstBeatMiss
$0.46$1.14$1.82$2.50$3.18Q1'25Q2'25Q3'25Q2'26Q3'26Q4'26
QtrEstActual+/−
Q4'26$1.65 - -
Q3'26$1.55$1.64+6.1%
Q2'26$1.57$1.39-11.5%
Q3'25$0.78$0.85+9.2%
Q2'25$2.21$2.87+29.7%
Q1'25$1.56$1.45-6.9%

Revenue

EstBeatMiss
$1.3B$1.5B$1.7B$1.9B$2.1BQ1'25Q2'25Q3'25Q2'26Q3'26Q4'26
QtrEstActual+/−
Q4'26$1.9B - -
Q3'26$1.7B$1.7B+0.1%
Q2'26$1.7B$1.7B+0.0%
Q3'25 - $1.4B -
Q2'25 - $2.0B -
Q1'25 - $1.7B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

CLX Stock Snapshot

CLX is currently trading at $97.28, giving The Clorox Company a market cap of 11.56B and a P/E ratio of 15.3. Today's range spans $94.86–$97.96, with shares opening at $97.00 and moving up $1.01 (1.0%) from the prior close. DailyIQ's technical score sits at 45/100 (HOLD) with a news sentiment reading of 47/100.

Over the past year CLX has traded between $84.70 and $132.03 - the current price is +14.9% off the 52-week low and -26.3% from the high. 28 analysts cover the stock with a Hold consensus and a mean 12-month target of $104.47 (range $77.00–$155.00), implying upside of +7.4%.

CLX is in consolidation mode: 45/100 technical score (HOLD), neutral sentiment at 47/100, price at $97.28 (in the lower half of its 52-week range within $84.70–$132.03). The current P/E ratio stands at 15.3. The 11.56B market cap in Consumer Defensive means the stock is widely covered and any shift in analyst sentiment or earnings expectations will be immediately reflected in price - making the current neutral phase a good time to track upcoming catalysts closely.

The 52-week range of $84.70–$132.03 for CLX provides the structural reference that options traders, systematic funds, and discretionary managers all anchor to — and at $97.28 (in the lower half of its 52-week range), the stock sits in a zone where the next 5–10% move will likely define which crowd was right. A HOLD signal at 45/100 and neutral news backdrop (47/100) don't break the tie yet, but they narrow the probability distribution toward the upside.